Popular Trials
Anti-metabolites
Decitabine for Myelofibrosis
Recruiting1 awardPhase 2
Chicago, Illinois
This trial looks at the side effects and effectiveness of decitabine in treating patients with myelofibrosis, a cancer of the blood system. Decitabine may block proteins that turn certain genes off in various cancers including myelofibrosis.
Poly (ADP-ribose) polymerase (PARP) inhibitor
Pacritinib + Talazoparib for Myeloproliferative Disorders
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial is a study to find the appropriate dosage of talazoparib when given with pacritinib, a standard treatment. The goal is to determine the maximum tolerated dosage and the recommended
Monoclonal Antibodies
Canakinumab for Myelofibrosis
Recruiting1 awardPhase 2
New York, New York
This trial is testing Canakinumab as a treatment for primary myelofibrosis, post essential thrombocythemia/polycythemia vera related MF. Eligible patients will receive Canakinumab administered as a subcutaneous injection every 3 weeks for a core study period of 8 cycles.
Tyrosine Kinase Inhibitor
TL-895 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Canton, Ohio
This trial tests TL-895, a new oral medication, for treating Myelofibrosis, a type of bone marrow cancer. It targets patients who haven't tried certain treatments or didn't respond well to previous medications. TL-895 works by blocking enzymes that help cancer cells grow.
Popular Filters
Trials for Acute Myeloid Leukemia Patients
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Anti-metabolite
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Stem Cell Transplant for Lymphoma
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial looks at a procedure to help patients with graft failure. The procedure uses CD34 selected grafts to reduce risk of graft versus host disease. It is safe & effective & is being tested for malignant & non-malignant conditions.
Trials for Prolymphocytic Leukemia Patients
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Anti-metabolite
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Stem Cell Transplant for Lymphoma
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial looks at a procedure to help patients with graft failure. The procedure uses CD34 selected grafts to reduce risk of graft versus host disease. It is safe & effective & is being tested for malignant & non-malignant conditions.
Phase 3 Trials
Bromodomain and Extra-Terminal Protein Inhibitor
Pelabresib for Myelofibrosis
Recruiting1 awardPhase 3
La Jolla, California
This trial tests a new drug combination of pelabresib and ruxolitinib in patients with myelofibrosis who haven't tried certain treatments before. Pelabresib blocks harmful proteins, and ruxolitinib stops harmful signals to see if this combination works better.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
Recruiting2 awardsPhase 3
Commack, New York
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Luspatercept for Myelofibrosis
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Epigenetic Modulator
Bomedemstat for Blood Disorders
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Small Molecule Inhibitor
KRT-232 for Myelofibrosis
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
Trials With No Placebo
JAK Inhibitor
Peritransplant Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 2
Seattle, Washington
This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
Recruiting2 awardsPhase 3
Commack, New York
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.